On Dec. 5, 2017, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Ozempic (semaglutide injection). Ozempic was indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

Ozempic, the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide 1 (GLP-1) receptor agonist.